Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mycophenolic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 known ✓ | P12268 | 20/20 | 0.98 |
| ▸ | IMPDH1 known ✓ | P20839 | 10/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | HPGD | P15428 | 1/20 | 0.98 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.98 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.78 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.78 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.78 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.78 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.78 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.78 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.78 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.78 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mycophenolic Acid SCHEMBL9185989 | 1.00 | IMPDH2 (0.98) | IMPDH2IMPDH1KDM4EALDH1A1LMNA | |
| Mycophenolic Acid SCHEMBL1230249 | 0.99 | IMPDH2 (1.00) | IMPDH2IMPDH1KDM4EALDH1A1LMNA | |
| Mycophenolic Acid SCHEMBL29645054 | 0.99 | IMPDH2 (1.00) | IMPDH2IMPDH1KDM4EALDH1A1LMNA | |
| Mycophenolic Acid SCHEMBL5500098 | 0.99 | IMPDH2 (1.00) | IMPDH2IMPDH1KDM4EALDH1A1LMNA | |
| Mycophenolic Acid SCHEMBL1657813 | 0.99 | IMPDH2 (1.00) | IMPDH2IMPDH1KDM4EALDH1A1LMNA | |
| Mycophenolic Acid SCHEMBL2514376 | 0.99 | IMPDH2 (1.00) | IMPDH2IMPDH1KDM4EALDH1A1LMNA | |
| Mycophenolic Acid SCHEMBL4549 | 0.99 | IMPDH2 (1.00) | IMPDH2IMPDH1KDM4EALDH1A1LMNA | |
| Mycophenolic Acid SCHEMBL29380425 | 0.99 | IMPDH2 (1.00) | IMPDH2IMPDH1KDM4EALDH1A1LMNA | |
| Mycophenolic Acid SCHEMBL5259872 | 0.99 | IMPDH2 (1.00) | IMPDH2IMPDH1KDM4EALDH1A1LMNA | |
| Mycophenolic Acid SCHEMBL6502425 | 0.98 | IMPDH2 (0.98) | IMPDH2IMPDH1KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024038306-A1 | DIRECT PREPARATION OF MYCOPHENOLATE MOFETIL IN ANISOLE AND SIMPLE, ONE- POT ISOLATION OF ITS PURE OXALATE SALT | ALBORZ BULK PHARMACEUTICAL COMPANY (IR) | 2024-02-22 | — | — | WO | disclosed |
| CN-109789225-A | DNA MONOCLONAL ANTIBODIES TARGETING CHECKPOINT MOLECULES | 宾夕法尼亚大学理事会 | 2019-05-21 | — | — | CN | disclosed |
| CN-107405321-A | Use of short chain fatty acids in cancer prevention | 坦普尔大学 | 2017-11-28 | — | — | CN | disclosed |
| CN-106236741-A | For treating the Compounds and methods for of abnormal adrenal cortical cell disease | 密歇根大学董事会 | 2016-12-21 | — | — | CN | disclosed |
| CN-104302283-B | Compounds and methods for treating aberrant adrenocortical cell disorders | 密歇根大学董事会 | 2016-08-24 | — | — | CN | disclosed |
| CN-105848680-A | Treatment using bruton's tyrosine kinase inhibitors and immunotherapy | 药品循环有限责任公司 | 2016-08-10 | — | — | CN | disclosed |
| US-9139604-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2015-01-22 | — | — | US | disclosed |
| US-8871785-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130316969-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| WO-2004096286-A2 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096235-A2 | ANTI-CANCER PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096236-A2 | IMMUNOMODULATOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| EP-1421081-A4 | METHOD OF MYCOPHENOLATE MOFETIL PREPARATION | IVAX CR A S (CZ) | 2004-11-03 | — | — | EP | disclosed |
| EP-1421081-A1 | METHOD OF MYCOPHENOLATE MOFETIL PREPARATION | IVAX-CR a.s. (CZ) | 2004-05-26 | — | — | EP | disclosed |
| WO-2002100855-A1 | METHOD OF MYCOPHENOLATE MOFETIL PREPARATION | IVAX CORPORATION (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-0670724-A1 | USE OF MYCOPHENOLIC ACID, MYCOPHENOLATE MOFETIL OR DERIVATE THEREOF TO INHIBIT STENOSIS | SYNTEX (U.S.A.) INC. (US) | 1995-09-13 | — | — | EP | disclosed |
| WO-1994012184-A1 | USE OF MYCOPHENOLIC ACID, MYCOPHENOLATE MOFETIL OR DERIVATE THEREOF TO INHIBIT STENOSIS | SYNTEX (U.S.A.) INC. (US) | 1994-06-09 | — | — | WO | disclosed |
| EP-0281713-B1 | MORPHOLINOETHYLESTER OF MYCOPHENOLIC ACID AND DERIVATIVES THEREOF, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | SYNTEX (U.S.A.) INC. (US) | 1991-10-09 | — | — | EP | disclosed |
| EP-0281713-A1 | Morpholinoethylester of mycophenolic acid and derivatives thereof, their preparation and use in pharmaceutical compositions | SYNTEX (U.S.A.) INC. (US) | 1988-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | IMPDH2 246/4885IMPDH1 160/4885KDM4E 2471/4885 |
| US-20130316969-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | IMPDH2 246/4885IMPDH1 160/4885KDM4E 2471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.